Schwind PresbyMAX treats presbyopia with excimer surgery

Article

Schwind unveiled its PresbyMAX software module at ESCRS, a presbyopia solution for its AMARIS system. According to Schwind, the software makes it possible, for the first time, to treat emmetropic as well as myopic, hyperopic and astigmatic patients whose accommodative response is limited.

Schwind unveiled its PresbyMAX software module at ESCRS, a presbyopia solution for its AMARIS system. According to Schwind, the software makes it possible, for the first time, to treat emmetropic as well as myopic, hyperopic and astigmatic patients whose accommodative response is limited.

In contrast to other methods of treating presbyopia, PresbyMAX delivers bi-aspheric multifocal ablation profiles. Bi-aspheric refers to aspheric optimisation of the central corneal area for near vision and the midperipheral cornea for far vision of each patient eye. Near vision of presbyopic patients, even with additional visual defects like distance refraction and high-order aberrations, is significantly improved, providing sharper vision without the need for spectacles.

The software was developed by Schwind in cooperation with VISSUM under the direction of editorial advisory board member, Prof. Jorge Alio, Spain, and the OCIVIS group from the University of Alicante. He said: “The central development goal of PresbyMAX was to provide the first systematic and scientifically based approach for the correction of presbyopia with excimer laser surgery.”

Similar to multifocal contact lenses or refractive multifocal IOLs, PresbyMAX creates a multifocal corneal surface. Bi-aspheric multifocal ablation profiles are optimised using a predictive model based on a light propagation algorithm.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.